INS-VAGINAL ESTROGEN COVERAGE House SponsorsRep. Katie Stuart, Kelly M. Cassidy, Lilian Jiménez, Mary Beth Canty, Laura Faver Dias, Will Guzzardi, Maura Hirschauer, Robyn Gabel, Jennifer Gong-Gershowitz and Suzanne M. Ness Senate Sponsors(Sen. Meg Loughran Cappel) 8/4/2023HousePublic Act . . . . . . . . . 103-0420 5 ILCS 375/6.1155 ILCS 5/5-1069.365 ILCS 5/10-4-2.3105 ILCS 5/10-22.3f215 ILCS 5/356z.61 new215 ILCS 125/5-3from Ch. 111 1/2, par. 1411.2215 ILCS 130/4003from Ch. 73, par. 1504-3215 ILCS 165/10from Ch. 32, par. 604305 ILCS 5/5-16.8 Amends the Illinois Insurance Code. Provides that a group or individual policy of accident and health insurance or a managed care plan that is amended, delivered, issued, or renewed on or after January 1, 2024 and that provides coverage for prescription drugs shall provide coverage for vaginal estrogen, and that coverage for vaginal estrogen shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement. Makes conforming changes in the State Employees Group Insurance Act of 1971, the Counties Code, the Illinois Municipal Code, the School Code, the Health Maintenance Organization Act, the Limited Health Service Organization Act, the Voluntary Health Services Plans Act, and the Medical Assistance Article of the Illinois Public Aid Code.House Floor Amendment No. 2 Provides that a group or individual policy of accident and health insurance or a managed care plan that is amended, delivered, issued, or renewed on or after January 1, 2025 (rather than January 1, 2024) and that provides coverage for prescription drugs shall include coverage for one or more therapeutic equivalent versions of vaginal estrogen in its formulary.Senate Committee Amendment No. 1 Provides that if (rather than if an individual's attending provider recommends) a particular vaginal estrogen product or its therapeutic equivalent version approved by the United States Food and Drug Administration is determined to be medically necessary (rather than based on the provider's determination), the issuer must cover that service or item pursuant to the cost-sharing requirement in specified provisions (rather than without cost sharing). Provides that a policy subject to the provisions shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement that exceeds any deductible, coinsurance, copayment, or any other cost-sharing requirement imposed on any prescription drug authorized for the treatment of erectile dysfunction covered by the policy (rather than on the coverage provided). Removes language providing that a policy is not required to include all therapeutic equivalent versions of vaginal estrogen in its formulary so long as at least one is included and covered without cost sharing and in accordance with the provisions. 1/30/2023HouseFiled with the Clerk by Rep. Katie Stuart 1/31/2023HouseFirst Reading 1/31/2023HouseReferred to Rules Committee 2/15/2023HouseAssigned to Insurance Committee 2/28/2023HouseHouse Committee Amendment No. 1 Filed with Clerk by Rep. Katie Stuart 2/28/2023HouseHouse Committee Amendment No. 1 Referred to Rules Committee 2/28/2023HouseDo Pass / Short Debate Insurance Committee; 013-001-000 2/28/2023HouseHouse Committee Amendment No. 1 Tabled 3/1/2023HouseAdded Co-Sponsor Rep. Kelly M. Cassidy 3/1/2023HousePlaced on Calendar 2nd Reading - Short Debate 3/6/2023HouseAdded Co-Sponsor Rep. Lilian Jiménez 3/14/2023HouseSecond Reading - Short Debate 3/14/2023HousePlaced on Calendar Order of 3rd Reading - Short Debate 3/16/2023HouseHouse Floor Amendment No. 2 Filed with Clerk by Rep. Katie Stuart 3/16/2023HouseHouse Floor Amendment No. 2 Referred to Rules Committee 3/16/2023HouseAdded Co-Sponsor Rep. Mary Beth Canty 3/16/2023HouseAdded Co-Sponsor Rep. Laura Faver Dias 3/16/2023HouseAdded Co-Sponsor Rep. Will Guzzardi 3/16/2023HouseAdded Co-Sponsor Rep. Maura Hirschauer 3/16/2023HouseAdded Co-Sponsor Rep. Robyn Gabel 3/16/2023HouseAdded Co-Sponsor Rep. Jennifer Gong-Gershowitz 3/16/2023HouseAdded Co-Sponsor Rep. Suzanne M. Ness 3/20/2023HouseHouse Floor Amendment No. 2 Recommends Be Adopted Rules Committee; 004-000-000 3/23/2023HouseRecalled to Second Reading - Short Debate 3/23/2023HouseHouse Floor Amendment No. 2 Adopted by Voice Vote 3/23/2023HousePlaced on Calendar Order of 3rd Reading - Short Debate 3/23/2023HouseThird Reading - Short Debate - Passed 108-000-001 3/24/2023SenateArrive in Senate 3/24/2023SenatePlaced on Calendar Order of First Reading 3/24/2023SenateChief Senate Sponsor Sen. Meg Loughran Cappel 3/24/2023SenateFirst Reading 3/24/2023SenateReferred to Assignments 4/12/2023SenateAssigned to Insurance 4/14/2023SenateSenate Committee Amendment No. 1 Filed with Secretary by Sen. Meg Loughran Cappel 4/14/2023SenateSenate Committee Amendment No. 1 Referred to Assignments 4/18/2023SenateSenate Committee Amendment No. 1 Assignments Refers to Insurance 4/18/2023SenateSenate Committee Amendment No. 1 Adopted; Insurance 4/19/2023SenateDo Pass as Amended Insurance; 011-000-000 4/19/2023SenatePlaced on Calendar Order of 2nd Reading April 20, 2023 4/25/2023SenateSecond Reading 4/25/2023SenatePlaced on Calendar Order of 3rd Reading April 26, 2023 5/4/2023SenateThird Reading - Passed; 057-000-000 5/8/2023HouseArrived in House 5/8/2023HousePlaced on Calendar Order of Concurrence Senate Amendment(s) 1 5/9/2023HouseSenate Committee Amendment No. 1 Motion Filed Concur Rep. Katie Stuart 5/9/2023HouseSenate Committee Amendment No. 1 Motion to Concur Referred to Rules Committee 5/15/2023HouseSenate Committee Amendment No. 1 Motion to Concur Referred to Insurance Committee 5/16/2023HouseSenate Committee Amendment No. 1 Motion to Concur Recommends Be Adopted Insurance Committee; 012-000-000 5/17/2023HouseSenate Committee Amendment No. 1 House Concurs 113-000-000 5/17/2023HouseHouse Concurs 5/17/2023HousePassed Both Houses 6/15/2023HouseSent to the Governor 8/4/2023HouseGovernor Approved 8/4/2023HouseEffective Date January 1, 2024 8/4/2023HousePublic Act . . . . . . . . . 103-0420